Welcome to our dedicated page for Cencora SEC filings (Ticker: COR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how Cencora moves billions of dollars in branded, generic, and specialty drugs—and how much it sets aside for opioid litigation—means combing through dense regulatory documents. Cencora SEC filings explained simply is what most investors search for when a new disclosure lands. Stock Titan solves that problem by turning every freshly posted exhibit, footnote, and schedule into plain-English insights within minutes.
Our platform reads each Cencora annual report 10-K simplified, compares segment margins, and highlights cash-flow drivers hidden in accounting tables. You’ll also receive instant alerts the moment a director files Cencora Form 4 insider transactions real-time. Key features include:
- AI-powered summaries that clarify complex wording and accounting changes
- Real-time push notifications for new 10-K, 10-Q, 8-K, and Cencora insider trading Form 4 transactions
- Side-by-side visuals that streamline Cencora earnings report filing analysis
Whether you’re waiting for the next Cencora quarterly earnings report 10-Q filing, researching Cencora executive stock transactions Form 4, or need Cencora 8-K material events explained after an unexpected acquisition, everything is organized in one place. We even map the pages inside the Cencora proxy statement executive compensation section, so pay packages are only a click away. Stop downloading PDFs; start understanding Cencora SEC documents with AI that surfaces the metrics that matter.
Cencora, Inc. is a large global pharmaceutical sourcing and distribution company serving healthcare providers and drug manufacturers across human and animal health. It distributes branded, specialty, and generic drugs and provides services such as data analytics, reimbursement support, logistics, pharmacy management, and packaging.
In fiscal 2025, the company continued to execute a strategy focused on its core U.S. and international distribution businesses while expanding higher-margin manufacturer services. Cencora acquired an 85% stake in Retina Consultants of America for
Customer concentration is significant: Walgreens and Boots generated about
Cencora, Inc. (COR) President & CEO reports RSU activity. Director and executive Robert P. Mauch reported the vesting and conversion of 5,790 restricted stock units into common stock on 11/20/2025. These restricted stock units were granted for no cash consideration and are scheduled to vest in three equal installments on 11/20/2025, 11/20/2026 and 11/20/2027.
To cover tax withholding related to the vesting, 2,144 shares of common stock were disposed of at a price of $362.07 per share. After these transactions, Mauch beneficially owns 69,392 shares of Cencora common stock directly.
Cencora, Inc. (COR) Chief Financial Officer James F. Cleary reported equity compensation activity involving restricted stock units and common stock. On 11/20/2025, 1,876 restricted stock units with a conversion price of $0 were exercised into the same number of shares of common stock, increasing his directly held stake.
On the same date, 824 shares of common stock were disposed of at $362.07 per share to cover tax withholding tied to the vesting of these restricted stock units. After these transactions, Cleary directly owned 134,941.3479 shares of Cencora common stock. The restricted stock units were originally granted for no cash consideration and vest in three equal installments on 11/20/2025, 11/20/2026, and 11/20/2027.
Cencora, Inc. (COR)
To cover taxes on this vesting, 736 shares of common stock were withheld at a price of $362.07 per share. After these transactions, Campbell directly beneficially owned 27,242.141 shares of Cencora common stock.
Cencora, Inc. (COR) filed a Form 4 reporting equity activity by its SVP & Chief Accounting Officer, Lazarus Krikorian. On 11/20/2025, 1,023 shares of common stock were acquired through the vesting and settlement of previously granted restricted stock units. On the same date, 421 shares were disposed of at a price of $362.07 per share to cover tax withholding obligations.
After these transactions, Krikorian directly beneficially owned 21,185 shares of Cencora common stock and held 2,262 restricted stock units, which were originally granted for no cash consideration and vest in three equal installments on 11/20/2025, 11/20/2026, and 11/20/2027.
Cencora, Inc. executive Pawan Verma reported routine equity transactions on Form 4. On 11/20/2025, 1,974 restricted stock units were converted into shares of common stock, reflecting the vesting of a prior equity grant received for no consideration.
On the same date, 1,010 shares were withheld at a price of $362.07 to cover tax obligations tied to the vesting. After these transactions, Verma directly beneficially owned 5,148.05 shares of Cencora common stock and 3,948 restricted stock units remained outstanding.
Cencora, Inc. (COR) Executive Vice President Silvana Battaglia reported equity award activity in a Form 4. On 11/20/2025, 932 restricted stock units vested and were settled into an equal number of common shares. To satisfy tax withholding obligations tied to this vesting, 406 common shares were automatically disposed of at $362.07 per share. Following these transactions, she directly beneficially owned 20,473.464 Cencora common shares and held 1,865 remaining restricted stock units.
Cencora, Inc. (COR) President & CEO and director Robert P. Mauch reported routine equity transactions. On 11/18/2025, he exercised a non-qualified stock option to acquire 3,763 shares of common stock at an exercise price of $86.09 per share. On the same date, he sold 5,096 shares of common stock at a price of $366.64 per share under a pre-arranged Rule 10b5-1 trading plan adopted on 11/15/2024.
After these transactions, Mauch directly beneficially owned 65,746 shares of Cencora common stock and held 11,288 derivative securities in the form of stock options. The option exercised on 11/18/2025 related to a grant that became exercisable in four equal installments on 11/13/2020, 11/13/2021, 11/13/2022 and 11/13/2023.
COR reports that an affiliate intends to sell 5,096 shares of its common stock on the NYSE through Fidelity Brokerage Services LLC. The planned sale has an aggregate market value of 1,868,397.44, compared with 193,877,881 common shares outstanding.
The shares to be sold come from 1,333 shares acquired on 11/08/2024 via restricted stock vesting as compensation and 3,763 shares acquired on 11/18/2025 from an option granted on 11/13/2019 and paid for in cash. The seller, identified as Robert P. Mauch, has sold additional common shares during the past three months: 4,968 shares on 08/18/2025 for gross proceeds of 1,458,257.04; 5,097 shares on 09/18/2025 for 1,478,130.00; and 5,097 shares on 10/20/2025 for 1,665,699.60.
COR reported a planned stock sale under Rule 144 by shareholder Steven Collis. The notice covers the proposed sale of 31,349 common shares through Fidelity Brokerage Services on the NYSE, with an indicated aggregate market value of 11,493,797.36. The filing states that there were 193,877,881 common shares outstanding when the notice was prepared.
The shares to be sold come from 2,000 shares acquired via restricted stock vesting on 09/30/2023 and 29,349 shares acquired on 11/18/2025 through an option originally granted on 11/13/2019 and paid for in cash. Over the past three months, the same shareholder has sold additional common shares in several transactions, including 14,579 shares on 08/19/2025, 31,350 shares on 09/16/2025, 31,350 shares on 10/21/2025, and 50,000 shares on 11/06/2025, with gross proceeds disclosed for each sale.
FAQ
What is the current stock price of Cencora (COR)?
What is the market cap of Cencora (COR)?
